Medical Information

There are clear contraindications for the use of Sirolimus in combination with high-risk drugs, especially for severe liver dysfunction and the use of potent CYP3A4 inhibitors. Correctly identifying these risks is crucial for ensuring medication safety.

1. Severe liver dysfunction: Absolute contraindication

1.1 Core Taboos

Patients with severe liver dysfunction (such as Child Pugh grade C) are prohibited from using sirolimus.

This type of patient has a significant decrease in drug clearance ability, which can easily lead to drug accumulation and exacerbate liver damage.

1.2 Mild to moderate liver dysfunction

Such patients need to reduce or extend the dosing interval, and the specific plan will be personalized by doctors based on monitoring results.

Continuous monitoring of liver function and blood drug concentration is required during medication, and timely adjustments should be made.

2. Combination use of potent CYP3A4 inhibitors: high risk

2.1 Typical drug examples

Including ketoconazole, itraconazole, voriconazole, clarithromycin, telimycin, ritonavir, nivolumab, etc.

After combined use, the blood concentration of sirolimus will significantly increase (AUC can increase several times to more than ten times), greatly increasing the risk of poisoning (such as bone marrow suppression, interstitial pneumonia, etc.).

2.2 Joint use management plan

It is recommended to avoid combination therapy with potent CYP3A4 inhibitors.

If clinical use requires combination therapy, the dose of sirolimus must be significantly reduced (such as to 1/4 to 1/3 of the conventional dose), and blood drug concentration should be closely monitored (target trough concentration of about 5-8ng/mL), and further adjustments should be made based on the results.

3. Other taboos and high-risk groups

3.1 Absolute taboos

Individuals allergic to sirolimus or any of its excipients.

The use of CYP3A4 potent inhibitors that cannot be reduced and monitored (as above).

3.2 Other groups that require caution

Severe renal insufficiency: The safe dose has not been determined yet, and it needs to be reduced and renal function monitored.

Active infection: Medication should be considered after infection control, as it has immunosuppressive effects.

Pregnant and lactating women: may cause harm to the fetus or baby, and the pros and cons should be fully weighed.

4. Summary and Reminder

Before using sirolimus, it is essential to inform the doctor of a complete history of liver disease and all concomitant medications (including over-the-counter and herbal medicines).

Any dosage adjustment or combination therapy must be carried out under the guidance of a doctor and should not be changed by oneself.